ADOC regimen
WikiDoc Resources for ADOC regimen |
Articles |
---|
Most recent articles on ADOC regimen Most cited articles on ADOC regimen |
Media |
Powerpoint slides on ADOC regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on ADOC regimen at Clinical Trials.gov Clinical Trials on ADOC regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on ADOC regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on ADOC regimen Discussion groups on ADOC regimen Patient Handouts on ADOC regimen Directions to Hospitals Treating ADOC regimen Risk calculators and risk factors for ADOC regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for ADOC regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen
Overview
ADOC regimen refers to an immunochemotherapy regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.[1][2]
Regimen
H – Doxorubicin (Hydroxydaunomycin)
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Coiffier, Bertrand (2002-01-24). "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma". The New England Journal of Medicine. 346 (4): 235–242. doi:10.1056/NEJMoa011795. ISSN 1533-4406. PMID 11807147. Unknown parameter
|coauthors=
ignored (help) - ↑ Kluin-Nelemans, H. C. (2012-08-09). "Treatment of older patients with mantle-cell lymphoma". The New England Journal of Medicine. 367 (6): 520–531. doi:10.1056/NEJMoa1200920. ISSN 1533-4406. PMID 22873532. Unknown parameter
|coauthors=
ignored (help)